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Background: Recently, accumulating evidence has shown that exosomes, the naturally secreted nanocarriers of
cells, can exert therapeutic effects in various disease models in the absence of parent cells. However, application
of exosomes in bone defect repair and regeneration has been rarely reported, and little is known regarding their
underlying mechanisms.
Methods: Exosomes derived from human-induced pluripotent stem cell-derived mesenchymal stem cells
(hiPS-MSC-Exos) were combined with tricalcium phosphate (β-TCP) to repair critical-sized calvarial bone defects, and
the efficacy was assessed by histological examination. We evaluated the in vitro effects of hiPSC-MSC-Exos on the
proliferation, migration, and osteogenic differentiation of human bone marrow-derived mesenchymal stem cells
(hBMSCs) by cell-counting, scratch assays, and qRT-PCR, respectively. Gene expression profiling and bioinformatics
analyses were also used to identify the underlying mechanisms in the repair.
Results: We found that the exosome/β-TCP combination scaffolds could enhance osteogenesis as compared to pure
β-TCP scaffolds. In vitro assays showed that the exosomes could release from β-TCP and could be internalized by
hBMSCs. In addition, the internalization of exosomes into hBMSCs could profoundly enhance the proliferation,
migration, and osteogenic differentiation of hBMSCs. Furthermore, gene expression profiling and bioinformatics
analyses demonstrated that exosome/β-TCP combination scaffolds significantly altered the expression of a network
of genes involved in the PI3K/Akt signaling pathway. Functional studies further confirmed that the PI3K/Akt signaling
pathway was the critical mediator during the exosome-induced osteogenic responses of hBMSCs.
Conclusions: We propose that the exosomes can enhance the osteoinductivity of β-TCP through activating the
PI3K/Akt signaling pathway of hBMSCs, which means that the exosome/β-TCP combination scaffolds possess better
osteogenesis activity than pure β-TCP scaffolds. These results indicate that naturally secreted nanocarriers-exosomes
can be used as a bioactive material to improve the bioactivity of the biomaterials, and that hiPS-MSC-Exos combined
with β-TCP scaffolds can be potentially used for repairing bone defects.
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The effective reconstruction of bone defects is a challenging
problem in orthopedic surgery. Autologous and allogenic
bone grafting are the most widely used treatments for bone
defect repair. However, the limited availability of graft ma-
terial, the extra damage to harvest sites, and the frequent
need for a second operation suppressed autologous bone
grafts [1, 2]; allogenic bone grafts are hampered by prob-
lems of significant failure rates, poor mechanical stability,
and immunological rejection [3]. Bioactive materials pro-
vide an alternative solution for the repair and regeneration
of bone defects. Tricalcium phosphate (β-TCP), composed
of the same ions as bone, is a well characterized osteocon-
ductive biomaterial and is already in clinical use for bone
repair and regeneration [4, 5]. However, β-TCP is largely
considered to lack osteoinductive activity, which may
impact its repair capacity for large bone defects and non-
unions [6–8].
Mesenchymal stromal cells (MSCs) have been widely
studied for tissue repair and regeneration [9, 10]. Recently,
accumulating evidence has revealed that the positive effects
of MSCs on tissue repair are not facilitated by the direct
differentiation into the parenchymal cell that repairs and
replaces the damaged tissues, but rather by stimulating the
activity of tissue-resident recipient cells via paracrine
mechanisms [11–13]. Exosomes, the naturally secreted
nanocarriers from cells, are 40–150 nm nanoparticles ori-
ginating from multivesicular bodies, and play key roles in
intercellular communication by transferring proteins and
genetic information to target cells [14]. It has been re-
ported that MSC-derived exosomes have therapeutic po-
tential in various disease models in the absence of MSCs
[15–17]. In addition, exosomes have been reported to be
able to exhibit similar functional properties to the cells
from which they are derived and have no apparent adverse
effects [18–20]. Therefore, exosomes derived from MSCs
may also play a critical role in tissue regeneration.
However, collecting enough exosomes for tissue repair
relies on abundant parent cell sources. Recent studies
indicate that MSC-like cells derived from iPSCs
(iPS-MSCs) offer the advantages of both MSCs and
iPSCs. Specifically, abundant MSCs can be generated from
iPSCs that can be passaged >40 times in culture and still
sustain the self-renewal capacity characteristic of MSCs
[21]. iPS-MSCs also possess greater proliferative capacity
and immunoregulatory function compared with adult
MSCs [21, 22]. In addition, a previous study demonstrated
that iPS-MSCs had bone regeneration ability when they
were directly transplanted into calvarial defects in immuno-
compromised mice [23]. These features make iPS-MSCs an
excellent cell source for exosome generation. Considering
the similar therapeutic effects of exosomes to those of their
parent cells, we hypothesize that the exosomes derived
from iPS-MSCs may also have pro-osteogenesis ability.Thus, we propose to use exosomes to functionalize bioma-
terials and obtain an exosome/biomaterial combination in
order to improve the osteogenesis ability of biomaterials.
Therefore, we used human iPS-MSCs as cell sources to
generate exosomes (hiPS-MSC-Exos) and investigated
whether these naturally secreted nanocarriers could en-
hance bone repair and the regeneration ability of β-TCP.
We combined hiPS-MSC-Exos with β-TCP scaffolds and
we verified that hiPS-MSC-Exos/β-TCP combination
scaffolds could significantly promote osteogenesis in a rat
model of critical-sized calvarial bone defect as compared
to β-TCP alone. In vitro studies, including the release of
exosomes from hiPS-MSC-Exos/β-TCP combination
scaffolds and internalization of exosomes into hBMSCs,
have been conducted. After internalization, the prolifera-
tion, migration, and osteogenic differentiation of hBMSCs
have been investigated. By using gene expression profiling
and bioinformatics analyses, we have proved that the exo-
somes can activate the PI3K/Akt signaling pathway, which
may be one of the underlying mechanisms through which
hiPS-MSC-Exos/β-TCP combination scaffolds stimulate
osteogenesis as compared to β-TCP alone.Methods
Generation and characterization of hiPS-MSCs
A comprehensive method description and results on the
derivation and characterization of hiPS-MSCs have been
provided in our previous publications [13, 24]. Briefly,
the human iPS cells were routinely cultured and ex-
panded on ESC-Qualified BD Matrigel (BD Biosciences,
Sparks, USA) in six-well plates in mTESR1 (StemCell
Technologies, Vancouver, Canada). When cells were
90 % confluent, mTESR1 was replaced by low-glucose
Dulbecco’s modified Eagle medium (Corning, Tewksbury,
USA) containing 10 % fetal bovine serum (FBS; Gibco,
Grand Island, USA) and 2 mM L-Glutamine (Gibco,
Grand Island, USA). The medium was changed every
other day. After 14 days in culture, the cells were trypsi-
nized and resuspended in MSC media and plated onto
0.1 % gelatin-precoated dishes. Cells were passaged when
they reached 80–90 % confluency.
Usually, cells at passage 4 exhibited a typical MSC-like
morphology and were used for cell surface marker iden-
tification by flow cytometry analysis. Briefly, 5 × 105 cells
were fixed with 4 % paraformaldehyde for 15 min,
blocked with 3 % BSA in PBS for 30 min, and incubated
with the following primary antibodies (BD Biosciences):
CD29, CD34, CD73, CD90, CD105, and HLA-DR. Non-
specific fluorescence was determined by incubation of
similar cell aliquots with isotype-matched mouse mono-
clonal antibodies. The cells were washed with PBS and
analyzed using the Guava easyCyte™ Flow Cytometer
(Millipore, Billerica, MA, USA).
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qRT-PCR measurement of gene expression levels of
markers associated with osteo- (OCN), chondro- (Sox9),
and adipogenic (LPL) differentiation after 7 days in cul-
ture with osteo-, chondro-, and adipogenic mediun.
Isolation and identification of hiPS-MSC-Exos
When hiPS-MSCs were 80–90 % confluent, the culture
medium was replaced by the MGro-500 chemically de-
fined serum-free MSC medium (StemRD), and the cells
were cultured for an additional 48 h. The conditioned
medium (CM) of hiPS-MSCs was obtained and centri-
fuged at 300 × g for 10 min and at 2000 × g for 10 min to
remove dead cells and cellular debris. Then, the super-
natant was filtered through a 0.22-μm filter sterilizer
(Steritop TM; Millipore, Billerica, USA) to remove the re-
sidual cellular debris. Subsequently, the supernatant was
centrifuged at 4000 × g to about 200 μL by ultra-filtration
in a 15 mL Amicon Ultra-15 Centrifugal Filter Unit
(Millipore, Billerica, USA). The ultra-filtrated liquid was
washed twice with 15 mL PBS and re-ultra-filtrated at
4000 × g to 200 μL. For exosome purification, the liquid
was overlaid onto a 30 % sucrose-D2O cushion in a sterile
Ultra-Clear™ tube (Beckman Coulter, Kraemer Boulevard
Brea, USA) and ultra-centrifuged at 100,000 × g for 2 h to
pellet the small vesicles that correspond to exosomes. The
pelleted exosomes were resuspended in 15 mL PBS and
centrifuged at 4000 × g in Centrifugal Filter Units until the
final volume was reduced to approximately 200 μL. All
procedures were performed at 4 °C. Exosomes were stored
at –80 °C or used for downstream experiments. Transmis-
sion electron microscopy (TEM), tunable resistive pulse
sensing (TRPS) analysis, and western blotting were used
to identify hiPS-MSC-Exos.
In vivo animal experiments
Surgical procedures
All procedures were approved by the Animal Research
Committee of the Sixth People’s Hospital, Shanghai Jiao
Tong University, China. Classical porous tricalcium phos-
phate (β-TCP) scaffolds with a dimension of 5 mm in
diameter and 2 mm in depth (Bio-lu Biomaterials Co.
Ltd., Shanghai) with an average pore size of 500 μm and
75 % porosity were used as exosome carriers in the in vivo
studies. Five × 1011 particles/mL or 1 × 1012 particles/mL
of exosomes (100 μL) or an equal volume of exosome di-
luent (PBS) were blotted onto each β-TCP scaffold under
sterile conditions and left still for at least 4 h for the exo-
somes to be totally absorbed. Sprague-Dawley (SD) rats
weighing 250–300 g were anesthetized, and two critical-
sized calvarial defects with a diameter of 5 mm were cre-
ated on each side of the cranium using dental trephine
followed by implantation of the scaffolds into the defects.
Eighteen rats were randomly divided into three groups forthe following implants: (1) β-TCP (n = 6); (2) β-TCP +
Exos (5 × 1011 particles/mL) (n = 6); and (3) β-TCP + Exos
(1 × 1012 particles/mL) (n = 6). At 8 weeks after surgery,
the rats were sacrificed and the craniums were harvested.
Craniums were first analyzed by micro-CT. Then, every
cranium was divided into two halves, one for non-
decalcified histological analysis and the other for decalci-
fied immunohistochemical (IHC) analysis.
Sequential fluorescent labeling
At 2, 4, and 6 weeks after the operation, all the rats were
intraperitoneally injected with tetracycline (25 mg/kg
body weight), alizarin red (30 mg/kg body weight), and
calcein (20 mg/kg body weight), respectively. The tri-
chromatic sequential fluorescent assessment was per-
formed to observe the mineralized tissue.
Micro-CT analysis
At 8 weeks after the operation, every rat was euthanized,
and craniums were then explanted and fixed in 10 %
neutral buffered formalin solution for longer than 48 h.
The craniums were scanned using micro-CT (Skyscan
1176, Kontich, Belgium) at 18-μm resolution. Three-
dimensional grayscale images were generated using the
CTVol program. As there are density differences be-
tween β-TCP and new bone, CTAn software used in this
study can distinguish one from the other. Then, per-
centage of new bone volume relative to tissue volume
(BV/TV) and bone mineral density (BMD) in the bone
defect were both calculated.
Histological and IHC analysis
Half of every fixed cranium was dehydrated through
graded alcohol series, and embedded in polymethylmetha-
crylate (PMMA). After hardening, the sagittal sections of
the central segment were cut into 150–200-μm thick
slices using a microtome (Leica, Hamburg, Germany) and
glued onto a plastic support and polished to a final thick-
ness of approximately 40 μm. Subsequently, a confocal
laser scanning microscope (Leica, Heidelberg, Germany)
was used to observe fluorescent labeling of the sections
with chelating fluorochromes employing the excitation/
emission wavelengths of 405/580 nm for tetracycline
(yellow), 543/617 nm for alizarin red (red), and 488/
517 nm for calcein (green). The sections were stained with
van Gieson’s picrofuchsin and were observed with a
microscope (Leica, Solms, Germany) to assess new bone
formation. In the image, red and black indicated new bone
and β-TCP, respectively. The other half of the craniums
was decalcified for 2 to 3 weeks in 10 % EDTA solution,
dehydrated with gradient alcohols, embedded in paraffin,
and then sectioned into 4-mm thick sections. Osteogen-
esis was evaluated by IHC analysis for osteocalcin (OCN).
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Cell culture
Human BMSCs (hBMSCs) were obtained from four donors
(the donors at an average age of 35 are healthy in daily life,
but are amputees due to trauma) with written informed
consent. Briefly, the marrow of the femora midshaft was ex-
tracted and then suspended in α-MEM containing 10 %
fetal bovine serum (FBS; Hyclone), 100 U/mL penicillin,
and 100 mg/mL streptomycin (Hyclone). Non-adherent
cells were removed and adherent cells were passaged after
becoming 80 % confluent. Early-passage BMSCs (p2–6)
were used in the experiments as described below.
Exosome release from β-TCP
hiPS-MSCs were labeled with Vybrant DiO (green) dye
(Molecular Probes, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Briefly, the cells were trypsi-
nized and resuspended in 1 mL MGro-500 serum-free
MSC media; 5 μL of the cell-labeling solution was added
to the cells, followed by incubation at 37 °C and 5 %
CO2 for 15 min. The labeled cell suspension was centri-
fuged at 300 × g for 15 min and the supernatant was dis-
carded. The cells were washed three times with PBS and
then cultured in MSC media for an additional 24 h. To
detect exosome release from β-TCP, exosomes isolated
and purified from the hiPS-MSC-derived CM were com-
bined with β-TCP and then added to the 24-well plate
when hBMSCs were about 80–90 % confluent. After cul-
turing for 8 h in this medium, the exosome/β-TCP com-
bination was removed and added to another well. The
hBMSCs were washed twice with PBS, fixed with 4 %
paraformaldehyde for 15 min, and stained with DAPI for
5 min at room temperature. After that, the cells were ana-
lyzed with a fluorescence microscope (Leica DMI6000B,
Solms, Germany) to observe the release of exosomes. The
detection of exosomes released from β-TCP was carried
out for 2 days.
The release rate of exosomes from TCP was also detected
by TRPS analysis. Briefly, 1 × 1012 particles of exosomes
were combined with β-TCP and then added to the 24-well
plate supplemented with 200 μl PBS. After culturing for
1 day, the PBS was collected and refilled with 200 μl fresh
PBS. The detection was carried out for 5 days. The particles
in PBS were finally counted by TRPS analysis.
Cell proliferation assay
A Cell Counting Kit-8 assay (CCK-8; Dojindo, Kyushu
Island, Japan) was performed to assess cell proliferation
as previously described [7]. Briefly, hBMSCs (5 × 103
cells per well) were seeded onto 96-well plates and
cultured at 37 °C in MSC media supplemented with
5 × 1011 or 1 × 1012 particles/mL of exosomes. Cells
treated with an equal volume of PBS served as controls,
and a group without cells served as the blank. At day 1, 2,3, 4, and 5, CCK-8 solution (10 μL per well) was added to
hBMSCs and subsequently incubated at 37 °C for 3 h. The
absorbance was measured at 450 nm using a microplate
reader. The optical density (OD) values represented the
survival/proliferation of hBMSCs.
Migration assay
Cell migration was assessed using a scratch wound healing
assay as previously described [24]. Briefly, hBMSCs
(1 × 105 cells per well) were plated in 12-well plates and
incubated at 37 °C. After cells had attached, the confluent
monolayer was scratched using a p200 pipette tip and
washed with PBS to remove the debris and smooth the
edge of the scratch; 1 mL of MSC medium supplemented
with exosomes (5 × 1011 or 1 × 1012 particles/mL) or an
equal volume of PBS was added to each well. The cells
were photographed immediately (t = 0 h), and 12 h
(t = 12 h) and 24 h (t = 24 h) later using a microscope (Leica
DMI6000B, Solms, Germany). The migration area (%) was
assessed as follows: migration area (%) = (A0 – An)/
A0 × 100, where A0 represents the initial wound area
(t = 0 h) and An represents the residual area of the
wound at the metering point (t = n h).
Gene expression profiling and bioinformatics analysis
hBMSCs were seeded in a 25-cm2 cell culture flask and
cultured in MGro-500 serum-free MSC medium con-
taining exosomes (5 × 1011 particles/mL) or an equal
volume of PBS at 37 °C, 5 % CO2 for 24 h. Gene expression
profiling analyses of hBMSCs were performed by using the
GeneChip® PrimeView™ Human Gene Expression Array
(Affymetrix, Santa Clara, CA, USA), which contained ap-
proximately 20,000 annotated Homo sapiens gene probes.
The experiments were performed in triplicate. A p value
cut-off of 0.05 and a fold-value change of ≥2 were used as
a filter to identify the differentially expressed (DE) genes.
The expression values of differentially expressed genes were
transformed to Z-scores and then hierarchically clustered
based on Euclidean distance and average-linkage. Then, a
gene set enrichment analysis of all differentially expressed
genes was performed based on the Database for Annotation
as well as Visualization and Integrated Discovery (DAVID)
to identify the significantly enriched pathways. The 1.5-fold
up- or downregulated genes in the selected enriched path-
ways were then illustrated as a heat map.
Quantitative real-time PCR analysis (qRT-PCR)
The expression levels of selected differentially expressed
genes after the functional enrichment analysis were con-
firmed by qRT-PCR. Total RNAs were extracted using Tri-
zol Reagent (Invitrogen, USA) and reverse-transcribed into
complementary (c)DNAs using the RevertAid first-strand
cDNA synthesis kit (Fermentas, Life Sciences, Burlington,
Canada). The qRT-PCR analysis was performed using an
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GAPDH was employed as the housekeeping gene for in-
ternal normalization. Primers used in the amplification re-
action are listed in Additional file 1 (Table S1).
Western blot analysis
Western blotting was performed as described previously
[7]. Cells or exosome lysates were diluted at a ratio of 1:4
with protein loading buffer (5×) and heated at 95 °C for
5 min. Protein extracts were separated on a 10 % sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel at 120 V for 1 h and blotted onto nitrocellulose
membranes (Whatman, Maidstone, Kent, UK) for 30 min
at 100 mA. The membranes were then blocked for 2 h with
5 % non-fat dried milk in TBST (10 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1 % Tween-20). Subsequently, the mem-
branes were incubated with primary antibodies at 4 °C
overnight, followed by incubation with horseradish peroxid-
ase (HRP)-labeled secondary antibodies (Cell Signaling
Technology, USA) at 37 °C for 1 h. The primary antibodies
including anti-CD9, anti-CD63, anti-CD81, anti-OCN, anti-
runt-related transcription factor 2 (Runx2), anti-collagen
type I alpha 1 (COL1A1), anti-Akt, and phosphorylated Akt
(p-Akt) antibody were obtained from Abcam (Cambridge,
UK). The immunoreactive bands were visualized using
enhanced chemiluminescence reagent (Thermo Fisher
Scientific, Waltham, MA, USA) and imaged by an
Image Quant LAS 4000 mini bio-molecular imager
(GE Healthcare, Uppsala, Sweden). All values were nor-
malized to the value of beta-actin (β-actin).
Alkaline phosphatase (ALP) assay and Alizarin red S (ARS)
staining
hBMSCs were cultured in osteogenic media supplemented
with exosomes or PBS for 10 days (ALP staining) or
14 days (ARS staining). Cells were washed with PBS, fixed
with 4 % paraformaldehyde for 10 mins, and incubated
with the ALP reagents (Sigma) or with 2 % ARS solution
(Sigma) for 30 min at 20 °C according to the manufac-
turer’s protocol. After washing with distilled water, theFig. 1 Characterization of exosomes derived from human induced pluripoten
observed by TEM. b Particle size distribution and concentration measured bystained cells were examined using an inverted microscope
(Leica DMI6000B, Solms, Germany). ALP activity of
hBMSCs was measured using a commercial kit (Sigma)
following the manufacturer’s instructions.
PI3K/Akt signaling inhibition
LY294002, a highly selective inhibitor of PI3K, was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) and
dissolved in dimethylsulfoxide (DMSO) at a stock con-
centration of 100 mM according to the manufacturer’s
protocol. To confirm the involvement of PI3K/Akt sig-
naling in the exosome-mediated effects on hBMSCs,
cells were pre-treated with the indicated concentration
(10 μM) of LY294002 or an equal volume of DMSO for
1 h. Subsequently, 5 × 1011 particles/mL of exosomes or
an equal volume of PBS was added to the culture
medium of hBMSCs and the cells were cultured for
24 h. Western blotting, ALP, and ARS staining on
hBMSCs were then performed as described above.
Statistical analysis
All data are shown as mean ± standard deviation (SD).
Differences between groups were assessed by one-way
analysis of variance (ANOVA); Dunnett t or LSD t ana-
lyses were performed to determine the statistical signifi-
cance between each sample. P < 0.05 was considered
statistically significant.
Results
Characterization of hiPS-MSCs and hiPS-MSC-Exos
Using a modified one-step induction protocol [25], almost
100 % of the hiPS cells successfully differentiated into
hiPS-MSCs, and the hiPS-MSCs exhibited characteristics
of MSCs (Additional file 1: Figure S1). TEM, TRPS ana-
lysis, and western blotting were used to characterize the
purified nanocarriers derived from hiPS-MSCs. The
results showed that the vast majority of these particles
exhibited a cup- or round-shaped morphology with a size
ranging from 50 to 150 nm (Fig. 1a and b), suggesting the
presence of exosomes. Also, these particles did express thet stem cell-derived mesenchymal stem cells (hiPS-MSCs). a Morphology
TRPS. c Western blot analysis of the exosome surface markers
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CD63, and CD81 (Fig. 1c), which further confirmed their
exosome identity. The data suggested that these nanocar-
riers were predominantly exosomes.In vivo osteogenesis activity of exosome/β-TCP
combination scaffolds
To investigate the therapeutic potential of hiPS-MSC-Exos
on bone repair, the rat critical-sized calvarial bone defect
model was established and the exosome/β-TCP com-
bination scaffolds were implanted into the defect areas.
High-resolution micro-CT scanning was carried out to
qualitatively evaluate the newly formed bone within the
defects at 8 weeks post-implantation. The sagittal view of
micro-CT images rarely, if at all, showed the newly rege-
nerated bone in the pure β-TCP group (Fig. 2a). On the
contrary, a large amount of de novo bone formation was
observed in the calvarial defect sites following implantation
with the β-TCP scaffolds loaded with 5 × 1011 particles/mL
of exosomes. Also, a larger extent of bone regeneration was
shown with an increasing exosome concentration. This was
confirmed by a quantitative analysis of the BV/TV (Fig. 2b),
which showed a dose-dependent increase in new bone for-
mation in the exosome-functionalized group as compared
to the control. Furthermore, the local BMDs showed the
same tendency as that obtained for the BV/TV levels
(Fig. 2c), indicating that hiPS-MSC-Exos could improve os-
sification in the defect areas.
The tetracycline (yellow), alizarin red (red), and calcein
(green) dyes were intraperitoneally injected into each rat
at 2, 4, and 6 weeks post-operation, respectively. Results
showed that the percentages of tetracycline (yellow),
alizarin red (red), or calcein (green) labeling in the
exosome-functionalized group were greater than those in
the control group (Fig. 2d and e). Higher percentages of
fluorescent dyes were observed after the bone defects were
treated with a higher concentration of exosomes (Fig. 2d
and e). Moreover, histological evidence based on van
Gieson staining of non-decalcified craniums demonstrated
that exosome treatment increased the newly formed bone
tissues within the defect areas, as determined by the
percentage of new bone area (Fig. 3a and b). Consistent
with the above findings, OCN immunostaining further
confirmed that the osteogenic responses from the defect
tissues treated with exosomes was enhanced as compared
to the control (Fig. 3c). Collectively, our in vivo functional
studies demonstrated that hiPS-MSC-Exos could stimu-
late osteogenesis of β-TCP through activating a bone
regenerative process in the target tissue.Exosome release from β-TCP
To detect exosome release from β-TCP, we used a green
fluorescent lipophilic dye (DiO) to label hiPS-MSCs. Theexosomes released by the labeled cells were also labeled
with DiO upon fusion of multivesicular bodies with the cell
plasma membrane. The labeled exosomes were combined
with β-TCP and then added to the plate containing
hBMSCs. The internalization of exosomes was detected
every 8 h of culture with hBMSCs. The results showed that
the DiO-labeled exosomes can be found in the perinuclear
region of hBMSCs which surround β-TCP (Fig. 4Aa), indi-
cating that hBMSCs are targets of hiPS-MSC-Exos.
As shown in Fig. 4Ab, the exosomes showed burst release
from β-TCP. In addition, with an increase in immersed
hours, exosome release decreased gradually.
Pro-osteogenesis effects of exosomes on hBMSCs
To explore the functional roles of hiPS-MSC-Exos in
osteogenesis, hBMSCs were cultured in MGro-500 MSC
or osteogenic medium containing exosomes (5 × 1011 or
1 × 1012 particles/mL) or in an equal volume of PBS for a
series of in vitro osteogenesis-related assays. Data indi-
cated that 5 × 1011 particles/mL of exosomes were able to
significantly enhance hBMSC proliferation; the hBMSCs
treated with a higher concentration of exosomes (1 × 1012
particles/mL) showed much higher proliferative capability
(Fig. 4B). As the resident MSCs are recruited into injury
sites for helping repair the injury, the migration ability of
MSCs is critical for bone reparation and regeneration. The
scratch wound assay showed that, after being cultured
with exosomes, the migration ability of hBMSCs was
remarkably enhanced (Fig. 4C and D). Detection of
ALP expression, a biochemical marker of osteogenesis as
well as the osteocalcin content, showed that incubation of
hBMSCs with hiPS-MSC-Exos resulted in a dose-
dependent increase in the ALP staining (Fig. 4E) and
activity (Fig. 4F), clearly indicating a positive role for hiPS-
MSC-Exos in osteogenic differentiation. Taken together,
our results show that hiPS-MSC-Exos could activate a
series of bone regenerative responses from target hBMSCs
in a dose-dependent manner. Taking economic concerns
into account, and since the low dose of exosomes
(5 × 1011 particles/mL) exert significant pro-osteogenic
effects on target tissues and cells, we used the con-
centration of 5 × 1011 particles/mL for the subsequent
experiments.
Differentially expressed genes in hBMSCs stimulated by
exosomes
To determine the effector genes that respond to hiPS-
MSC-Exos stimulation, microarray analyses of hBMSCs
cultured with exosomes or PBS were performed. The
1.5-fold up- or downregulated genes in all three paired
samples were defined as differentially expressed genes or
effector genes after exposure to hiPS-MSC-Exos. The
results showed that there was a significant differential
expression of 1447 candidate genes between the two
Fig. 2 Micro-CT and fluorochrome-labeling histomorphometrical analysis of the repaired craniums at 8 weeks post-implantation. a Three-dimensional
reconstruction and sagittal images show the different reparation effects of exosomes or tricalcium phosphate (β-TCP) only. b The bone volume/tissue
volume (BV/TV) and c bone mineral density (BMD) varied between the different groups. d Fluorochrome-labeling histomorphometrical analysis of new
bone formation and mineralization at 8 weeks post-operation (yellow, between 2 and 4 weeks; red, between 4 and 6 weeks; green, between 6 and
8 weeks). e Percentage of each fluorochrome area for different groups. Dunnett t test; *p < 0.05 compared with the β-TCP group, #p < 0.05 compared
with the exosome (Exos) 5 × 1011 particles/mL group
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upregulated and 1154 genes were downregulated in the
exosome-treated hBMSC groups than in the control
group treated with PBS. We then performed functional
enrichment analysis, including molecular functions and
involvement of all differentially expressed genes in
known regulatory signaling pathways. The resultsrevealed that multiple biological pathways were promin-
ently enriched (Enrichment Score >2.0, p < 0.05). The
top ten enriched pathways associated with exosome
stimulation are shown in Fig. 5b. Among these, extracel-
lular matrix (ECM)-receptor interaction, focal adhesion,
and phosphatidylinositol 3-kinase (PI3K)-Akt signaling
pathways appeared to be the most enriched ones
Fig. 3 Histological and immunohistochemical analysis of the newly formed bone after 8 weeks of transplantation. a The un-decalcified
craniums were stained with van Gieson’s picrofuchsin. The new bone area and tricalcium phosphate (β-TCP) residue are shown in red and
black, respectively. b Quantitative analysis of (a). Dunnett t test; *p < 0.05 compared with the β-TCP group, #p < 0.05 compared with the
exosome (Exos) 5 × 1011 particles/mL group. c The sections were subjected to immunohistochemical analysis to inspect the distribution of
OCN. OCN-positive immunostaining illustrated the bone tissues. Scale bars = 80 μm
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signaling pathway has previously been found to be in-
volved in MSC proliferation, migration, and osteogenic
differentiation [26–31], it is reasonable to believe that
this signaling process might have key roles in the
exosome-mediated pro-osteogenesis effects on hBMSCs.
The PI3K/Akt signaling pathway-related differentially
expressed genes are illustrated as a heat map (Fig. 5c)
showing that 117 genes involved in this pathway were al-
tered in hBMSCs treated with exosomes. Among them, 47
genes, such as platelet-derived growth factor alpha
(PDGFA), fibroblast growth factor 1 or 2 (FGF1/2), FGF
receptor 1 (FGFR1), collagen type I alpha 1 or 2
(COL1A1/2), and BCL2-like 1 (BCL2L1), which are posi-
tive effector genes in the PI3K/Akt signaling pathway,
were profoundly upregulated. Conversely, another 70
genes, such as glycogen synthase kinase 3 beta (GSK3β)
and phosphatase and tensin homolog deleted on chromo-
some ten (PTEN) that are key molecules in negatively
regulating this pathway, were markedly downregulated.
These results suggested that the PI3K/Akt signaling in
hBMSCs stimulated by hiPS-MSC-Exos was activated.To confirm the microarray results, 10 genes, including
VCAM1, FGF11, IL6, SLC2A1, ITGA7, LAMA1, ETNK1,
TLR4, DKK1, and NKTR, which were differentially
expressed between the exosome-treated BMSCs and the
control group (p < 0.05), were randomly selected for
qRT-PCR detection. The levels of VCAM1, FGF11, IL6,
SLC2A1, and ITGA7 were increased in the exosome-treated
hBMSCs, whereas the expression of LAMA1, ETNK1,
TLR4, DKK1, and NKTR was decreased (Additional file 1:
Figure S2). We also performed qRT-PCR to confirm the
altered expression of PI3K/Akt signaling-associated genes.
Data revealed that the exosome-treated hBMSCs showed a
profound upregulation of PDGFA, FGF1/2, FGFR1,
COL1A1/2, and BCL2L1, but a significant downregulation
of GSK3β and PTEN (p < 0.05) (Fig. 5d). The results were
generally consistent with the microarray data.
Involvement of PI3K/Akt signaling in the
exosome-induced osteogenic responses
The activation of the PI3K/Akt pathway in hBMSCs
following hiPS-MSC-Exos stimulation was verified by treat-
ing the cells with exosomes or PBS for 24 h and assessing
Fig. 4 Internalization of hiPS-MSC-Exos in human BMSCs, exosome release from β-TCP, and their pro-osteogenesis effects on the recipient cells.
A (a) DiO-labeled exosome release from β-TCP over 48 h. (b) Accumulated release of exosomes from β-TCP over 5 days. B Exosomes (Exos)
enhanced the proliferation of hBMSCs as analyzed by Cell Counting Kit-8 assay. C Exosomes stimulated the migration of BMSCs as analyzed by
migration assay. Scale bars = 250 μm. D Quantitative analysis of (C). E, F Incubation of hBMSCs with exosomes resulted in a dose-dependent
increase in the alkaline phosphatase (ALP) staining and activity. Dunnett t test; *p < 0.05 compared with the control group, #p < 0.05 compared
with the Exos 5 × 1011 particles/mL group
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Compared to the PBS control, incubation with hiPS-MSC-
Exos resulted in a significant increase in Akt phosphoryl-
ation on Ser473 in hBMSCs (Fig. 6a), indicating that the
PI3K/Akt signaling in hBMSCs was activated by the exo-
somes. However, the upregulation of p-Akt in hBMSCs by
the exosomes was significantly impaired after the hBMSCs
were cultured with a PI3K inhibitor (LY294002; 10 μM)
(Fig. 6a).
The activation of the PI3K/Akt pathway might be
the underlying mechanism through which hiPS-MSC-
Exos exert pro-osteogenesis effects on recipient cells.
We tested this hypothesis by culturing the BMSCs in
osteogenic media containing exosomes or PBS with or
without LY294002. After 7 days of differentiation,
Western blotting was performed to detect the levels
of the early osteogenesis-related marker proteinsincluding Runx2 and COL1, and the late osteogenic dif-
ferentiation marker OCN (Fig. 6a). The results revealed
that hBMSCs, when cultured in the osteogenic
medium, showed osteogenic differentiation as
indicated by the expression of osteogenesis-related
molecules. After incubation of hBMSCs with hiPS-
MSC-Exos, the levels of these osteogenesis-related pro-
teins were further increased. However, their upregulation
by hiPS-MSC-Exos was markedly suppressed by the PI3K
inhibitor LY294002. Furthermore, the addition of
LY294002 to the osteogenic medium alone also decreased
osteogenesis slightly, suggesting that the osteogenic
medium-induced osteogenesis relies on the activation of
the PI3K/Akt pathway to some extent. Also, we evaluated
the extent of ALP production and calcium mineral depos-
ition in hBMSCs by staining with ALP and ARS. As
shown in Fig. 6b, the exosome-treated hBMSCs showed
Fig. 5 Differential expression of mRNAs between exosome-treated and control groups. a The differentially expressed (DE) genes in hBMSCs in response to
exosome (Exos) stimulation are illustrated as a heat map. A p value cut-off of 0.05 and a fold-value change of ≥2 were used as a filter to identify the DE
genes. b Enrichment analysis of all DE genes was performed. The top ten enriched pathways associated with exosome stimulation are shown. c A heat
map of PI3K/Akt signaling pathway-related DE genes was generated. d The altered expression of PI3K/Akt signaling-related genes was confirmed by
qRT-PCR analysis. ANOVA; *p< 0.05 compared with the control group
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posits than the control group, whereas these effects were
blocked by the additional treatment with LY294002. The
ALP generation, matrix mineralization, and calcium
nodule formation were reduced slightly in BMSCs
treated with LY294002 compared with the control,which was consistent with the data from
osteogenesis-related molecule expression. Taken
together, our results indicated that the stimulatory
effects of hiPS-MSC-Exos on the osteogenic differen-
tiation of hBMSCs mainly resulted from the activation
of the PI3K/Akt signaling pathway.
Fig. 6 Involvement of PI3K/Akt signaling in the exosome-induced
osteogenic responses from BMSCs. a Exosomes (Exos) induced the
activation of the PI3K/Akt signaling pathway and increased the
protein levels of osteogenesis-related molecules; these effects by
exosomes were abolished by the PI3K inhibitor (LY294002; 10 μM).
b The exosome-treated hBMSCs showed much higher levels of alkaline
phosphatase (ALP) and Alizarin red S (ARS) staining compared with the
control groups on days 10 and 14, respectively; these effects were
inhibited by LY294002
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Normal healthy bone has the ability to spontaneously re-
generate after minor injury. However, extensive bone
loss due to disease or trauma requires tissue engineering
applications. In the present study, we provided the first
demonstration that hiPS-MSC-Exos, the nanocarriers
naturally secreted by iPS-MSCs, could be combined with
β-TCP and this hiPS-MSC-Exos/β-TCP combination
scaffold could significantly enhance osteogenesis in a rat
model of critical-sized calvarial bone defects as com-
pared to β-TCP alone. Through in vitro studies, we
found that the exosomes could remarkably promote
hBMSC osteogenic differentiation after they were inter-
nalized by hBMSCs through activating the PI3K/Akt sig-
naling pathway.
Currently, a growing body of evidence indicates that
MSC paracrine action may be applied as a novel strategy
for tissue repair [32, 33], and exosomes are important
paracrine factors that can be directly used as therapeutic
agents for various disease models, such as cutaneous
wound healing [24], myocardial infarction [34], trau-
matic brain injury [35], and immune disease [36]. How-
ever, it was unclear whether exosomes can be applied to
bone tissue engineering. β-TCP is a synthetic and bio-
degradable ceramic material that has been commonly
used for repairing bone defects, but the repair effect ofpure β-TCP is very limited as it lacks osteoinductive ac-
tivity. Considering the functional roles of exosomes in
tissue repair, we combined exosomes with β-TCP, hoping
to obtain an exosome/β-TCP composite scaffold which
could enhance osteogenesis. Based on imaging and
histological examinations in this study, we found that
the application of exosome/β-TCP combination scaffolds
in vivo could profoundly enhance bone regeneration
compared to pure β-TCP. Recently, the design of surface
morphological/topographies of TCP has been considered
a novel approach to enhance the bioactivity and osteoin-
ductive ability in the field of bone regeneration [6].
However, the technological process is relatively compli-
cated and the obtained bioactivity is very limited. Bone
tissue engineering has also been used, through which
bone regeneration can be achieved via a combination of
TCP with stem cells [4, 37]. Nevertheless, the application
of stem cells is still hampered by immunological
rejection, chromosomal variation, malignant transform-
ation, and so forth [38]. The therapeutic effects of exo-
somes on tissue injury have been demonstrated [24, 34–36].
In addition, MSC-derived exosomes do not contain MHC
class I or II proteins and, thus, their application to non-
immune-compatible animals does not induce overt im-
mune reactions [34, 39, 40]. Thus, the exosome/β-TCP
combination scaffolds can be potentially used as a promis-
ing graft for bone defect repair.
It is known that endogenous BMSCs can be mobilized
in response to injury, and the activated BMSCs can serve
as the major healing cells during bone repair and remodel-
ing [41]. We hypothesized that the beneficial effects of the
exosome/β-TCP combination scaffolds on bone defects
might be attributed to their recruitment and activation of
pre-existing BMSCs in the bone tissue, and we performed
in vitro experiments to confirm this hypothesis. It has
been proposed that exosomes can serve as a nanocarrier
to transfer proteins, mRNAs, and microRNAs from parent
cells to recipient cells, and that they alter the gene expres-
sion and protein translation of the recipient cells thereby
modulating the bioactivity of target cells [42]. Their in-
ternalization by target cells is the prerequisite for playing
such a role. In the present study, the DiO-labeled exo-
somes were combined with β-TCP, and then put into cell
culture plates containing hBMSCs. The labeled exosomes
can be seen in perinuclear regions of hBMSCs, indicating
exosomes could release from exosome/β-TCP com-
bination scaffolds and then be internalized by hBMSCs.
Further analysis showed that, after internalization of
exosomes into hBMSCs, they stimulate the proliferation,
migration, and osteogenic differentiation of hBMSCs.
These conditions are beneficial for attracting endogenous
BMSCs to bone defects and finally enhancing new bone
formation. All findings demonstrated that the exosome/
β-TCP combination scaffolds have obviously enhanced
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of exosomes.
We further clarified the molecular mechanisms of exo-
some/β-TCP combination scaffolds on the osteogenesis
of hBMSCs. Zhang et al. reported that the exosomes re-
leased by human umbilical cord blood-derived MSCs
were able to induce β-catenin nuclear translocation of
skin cells, enhancing their proliferation and migration
[43]. Shabbir et al. showed that the exosomes secreted
by human BMSCs could activate several signaling path-
ways (including Akt, Erk1/2, and STAT3) in target fibro-
blasts and increase their angiogenic response [44]. In
this study, we used microarray analysis to examine the
gene expression pattern in hBMSCs treated by hiPS-
MSC-Exos. We detected significant alterations in the ex-
pression of a variety of genes following treatment with
exosomes. Results of bioinformatics analyses indicated
that these significantly altered genes are predominantly
involved in the PI3K/Akt signaling pathway, focal adhe-
sion, and ECM-receptor interaction. In particular, the
PI3K/Akt pathway may have a role in the exosome-
induced pro-osteogenic effects on hBMSCs as this sig-
naling cascade has been reported to play important roles
in osteoblast differentiation and bone growth [26–28].
Here, we report that hiPS-MSC-Exos treatment resulted
in a prominent increase in the expression of the positive
effector genes of the PI3K/Akt pathway, such as PDGFA,
FGF1/2, FGFR1, COL1A1/2, and BCL2L1. All of these
genes can positively modulate cell survival, proliferation,
migration, osteogenic differentiation, or apoptotic inhib-
ition [29–31, 45, 46]. The typical negative modulators of
PI3K/Akt signaling, including GSK3β and PTEN, were
remarkably decreased. The results indicated that the
PI3K/Akt signaling in hBMSCs is probably activated
after internalization of exosomes. This contention was
confirmed by a significant increase in the phosphoryl-
ation of Akt (an indicator of PI3K activation) in hBMSCs
treated with exosomes. However, it is noteworthy that
the PI3K inhibitor markedly, but not completely, abol-
ished the pro-osteogenic effects of hiPS-MSC-Exos, sug-
gesting that the exosome-induced osteogenic effects
cannot be fully attributed to the PI3K/Akt pathway and
therefore additional mechanisms remain to be explored.
Our future studies will focus on deciphering the molecu-
lar contents of hiPS-MSC-Exos that underlie the activa-
tion of the PI3K/Akt signaling pathway that appears to
be largely responsible for the osteogenesis in hBMSCs.
Conclusions
In this study, we provided evidence that the hiPS-MSCs-
Exos-functionalized β-TCP scaffold can effectively promote
bone repair and regeneration in a rat model of calvarial
bone defects. The underlying mechanism through which
exosomes enhance osteoinductive activity of β-TCP andpromote bone regeneration appears to be the activation of
endogenous BMSCs in the bone defect site. This was sug-
gested by the observation that exosomes could release
from exosome/β-TCP combination scaffolds and then be
internalization by hBMSCs. Furthermore, the PI3K/Akt
signaling pathway likely plays a critical role in the pro-
osteogenesis effects of the exosome/β-TCP scaffold on
BMSCs. Further studies are needed to assess the long-term
effects of exosome-based therapy for bone repair and
whether the exosome-functionalized β-TCP can be used as
a valid and safe therapeutic option for clinical application.
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